Immunology – Page 2

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

4 months ago talkbio0Tagged alpha 1-antitrypsin, cardiometabolic, Eli, Eli Lilly, Generation Park, Houston, Immunology, Investments, Manufacturing, Neoplasms, Neuroscience discipline, pharmaceutical manufacturing, small molecule medicines

Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience

Novartis Inks Second Molecular Glue Deal With Monte Rosa Worth Up to $5.7 Billion

4 months ago talkbio0Tagged Autoimmune Diseases, Collaboration, Drug Discovery, Immunology, molecular glue degraders, Monte Rosa Therapeutics, Novartis, QuEEN, royalties, upfront payment

Novartis; Monte Rosa Therapeutics; molecular glue degraders; $5.7 billion deal; drug discovery; immunology; QuEEN platform; autoimmune diseases; upfront payment; royalties; collaboration

Pfizer Veteran Suneet Varma Named CEO of Phase 3-Ready Biotech Startup Intent Biologics

4 months ago talkbio0Tagged Appointments, biotech startup, CEO, Clinical Trials, Immunology, Inflammation, Intent Biologics, Pfizer vet, Phase 3, Regenerative Medicine, Suneet Varma

Suneet Varma; Pfizer vet; Intent Biologics; CEO appointment; regenerative medicine; Phase 3 clinical trials; biotech startup; inflammation and immunology

Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal

4 months ago talkbio0Tagged Autoimmune Diseases, Fosun Pharma, FXS6837, Immunology, License, Sitala

Fosun Pharma; Sitala; FXS6837; immunology; license agreement; autoimmune diseases; biotech; pharmaceuticals; $670 million

VantAI and Halda Strike $1B+ AI-Driven Partnership on ‘Hold-and-Kill’ Drugs

5 months ago talkbio0Tagged Artificial Intelligence, cellular targeting, Chimera organism, Drug Discovery, Halda Therapeutics, hold-and-kill, Immunology, Induce (action), Neoplasms, Proximity, RIPTAC, target-effector pairs, VantAI

VantAI; Halda Therapeutics; RIPTAC drugs; hold-and-kill; AI drug discovery; target-effector pairs; oncology; immunology; regulated induced proximity targeting chimeras; $1 billion deal

XtalPi and DoveTree Announce Landmark $6 Billion AI-Powered Drug Discovery Collaboration

5 months ago talkbio0Tagged Artificial Intelligence, Collaboration, Dosage Forms, DoveTree Medicines, Drug Discovery, Gregory Verdine, Immunology, Metabolic Diseases, milestone payments, Neoplasms, Neurology speciality, Robotics, royalties, upfront payment, XtalPi

XtalPi; DoveTree Medicines; AI drug discovery; robotics; pharmaceutical R&D; Gregory Verdine; oncology; immunology; neurology; metabolic diseases; collaboration; upfront payment; milestone payments; royalties

Bristol Myers Squibb Spins Out Five Immunology Assets into New $300M Biotech with Bain Capital

5 months ago talkbio0Tagged Afimetoran, Autoimmune Diseases, BMS-986322, Clinical Development, Immunology, Investments, Myers, squibb

Bristol Myers Squibb; Bain Capital; immunology; autoimmune disorders; biotech spinout; afimetoran; BMS-986322; clinical development; investment; new company